Stradling Client, Madrigal, Announces Merger Agreement with Synta Pharmaceuticals
April 2016
On April 14, 2016, Stradling client Madrigal, a privately-held pharmaceutical company, entered into a definitive agreement under which Madrigal will merge with a wholly-owned subsidiary of Synta Pharmaceuticals in an all-stock transaction. The merger will create a company focused on the development of small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis. Read full press release.